Approximately 3% of advanced NSCLC cases harbor point mutations or deletions in MET exon 14 or its flanking introns [47], while around 1% of poor survival NSCLC patients are associated with de novo MET amplification [108]. This evidence concerns the gene MET and non-small cell lung carcinoma.